Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.4154
-0.0079 (-1.87%)
At close: Feb 24, 2026, 4:00 PM EST
0.4023
-0.0131 (-3.15%)
Pre-market: Feb 25, 2026, 6:53 AM EST
Gossamer Bio Employees
As of December 31, 2024, Gossamer Bio had 145 total employees, including 144 full-time and 1 part-time employees. The number of employees increased by 10 or 7.41% compared to the previous year.
Employees
145
Change (1Y)
10
Growth (1Y)
7.41%
Revenue / Employee
$303,800
Profits / Employee
-$1,076,972
Market Cap
96.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 145 | 10 | 7.41% | 144 | 1 |
| Dec 31, 2023 | 135 | -43 | -24.16% | 135 | 0 |
| Dec 31, 2022 | 178 | -7 | -3.78% | 178 | 0 |
| Dec 31, 2021 | 185 | -11 | -5.61% | 185 | 0 |
| Dec 31, 2020 | 196 | 25 | 14.62% | 195 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Codexis | 188 |
| Precision BioSciences | 67 |
| aTyr Pharma | 65 |
| Vivani Medical | 37 |
| Cardiff Oncology | 33 |
| Cassava Sciences | 30 |
| Cognition Therapeutics | 28 |
GOSS News
- 1 day ago - Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript - Seeking Alpha
- 1 day ago - BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75% - GlobeNewsWire
- 1 day ago - Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 1 day ago - Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
- 1 day ago - Gossamer Bio's experimental lung condition drug fails in late-stage trial - Reuters
- 1 day ago - Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire
- 6 weeks ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Gossamer Bio to Participate in Upcoming Investor Conferences - Business Wire